BioStock: Mendus nears late-stage development with cancer relapse vaccine

Tumour recurrence is the underlying cause of the majority of cancer deaths worldwide. Tackling the issue is immuno-oncology company Mendus with the development of relapse vaccine DCP-001. Encouraging data has come from both a phase II trial in acute myeloid leukeamia and a phase I trial in ovarian cancer, which has been accompanied by funding by the European Commission as well as landing a manufacturing agreement aimed at late-stage and commercial production of DCP-001. Key survival data updates from the phase II study in AML are expected during Q4 this year.

Read the article at biostock.se:

Mendus nears late-stage development with cancer relapse vaccine - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/